Latest
news

LR Health & Beauty SE publishes figures for the first half of 2025 and adjusts its forecast for 2025

• EUR 142.9 million in sales achieved in the first half of 2025
• EBITDA reported improved by 13.6% to EUR 13.3 million
• Newly appointed management team with CEO Jörg Körfer and Interim CFO Ante Franicevic drives further development of corporate strategy
• Planned discussions with bondholders of the 2024/2028 bond regarding a precautionary resolution on a waiver of compliance with the Leverage Covenant as at 30 September 2025 and an amendment to the bond terms
• Sales and earnings guidance for financial year 2025 adjusted 

Ahlen, 28 August 2025 – LR Health & Beauty SE, Europe’s leading digital social commerce company for high-quality nutritional supplements and beauty products, today published its results for the second quarter and the first half of 2025. In the second quarter of the financial year 2025, LR Health & Beauty SE generated sales (revenue from goods sold) of EUR 68.9 million (Q2 2024: EUR 70.7 million) – a decline of 2.6%. In the first half of the year, sales amounted to EUR 142.9 million, representing a slight decrease of 0.3% compared with the prior-year figure of EUR 143.3 million. This development reflects the generally subdued consumer sentiment, particularly noticeable in Western European markets.

In addition, LR Health & Beauty SE achieved EBITDA reported of EUR 13.3 million in the first six months of 2025, representing a significant increase of 13.6% compared with the prior-year period (H1 2024: EUR 11.7 million). In the prior-year period, refinancing costs incurred in connection with the redemption of the previous bond had weighed on earnings. Normalized EBITDA increased by 6.3% to EUR 15.3 million in the first half of 2025 (H1 2024: EUR 14.4 million).

Valdemaras Gordinskis, Vice President Global Controlling and Investor Relations LR Health & Beauty SE, comments: “In the first half of 2025, we focused on further enhancing the foundations for the business success of our distributors. Our product innovations play an important role in this. Through regular product launches and the targeted expansion of our portfolio, we are opening up attractive business opportunities for our distributors in a generally challenging market environment.”

New leadership team with proven expertise

With a newly formed leadership team, LR is consistently driving the further development of its corporate strategy. As of 1 August 2025, Mr Jörg Körfer was appointed Chief Executive Officer (CEO). He brings extensive expertise in global direct sales from his many years of senior management positions at internationally operating companies, including Bofrost and Vorwerk. In addition, LR has strengthened its management team with the appointment of Mr Ante Franicevic, who serves as Interim Chief Financial Officer (CFO). Mr Franicevic contributes more than 20 years of senior management experience in finance at well-known retail and consumer brands such as Douglas, Jack Wolfskin and Metro.

Jörg Körfer, CEO of LR Health & Beauty SE, states: “As a newly formed leadership team, our clear goal is to continue LR’s success story as Europe’s leading social commerce company. Our Global Leader Convention in Berlin, marking the company’s 40th anniversary, and the Business Days in September provide an ideal opportunity to strengthen our engagement with our community members and to launch new business initiatives. Together with our distributors, we aim to make the company even stronger and more innovative, thereby ensuring sustainable success for LR in a challenging market environment.”

2024/2028 bond

Today, the Management Board of LR Health & Beauty SE resolved to initiate precautionary negotiations with the holders of the 2024/2028 bond (ISIN: NO0013149658) regarding a proposal to amend the bond terms and, if necessary, to request their consent to a waiver of the Leverage Covenant as at 30 September 2025. The background is a potential breach of the company’s obligation under Clause 13.2 of the bond terms, which requires the company to ensure that net debt in relation to EBITDA (the “Leverage Covenant”) does not exceed the threshold of 4.50:1 as at 30 September 2025. The Leverage Covenant was reduced from 4.75:1 to 4.50:1 as of 1 July 2025. Based on preliminary calculations, the Management Board currently assumes that the Leverage Covenant is unlikely to be met on the review date of 30 September 2025. This is due to EBITDA developing less favourably than expected, primarily due to increased or increasing costs in the areas of marketing and sales.

Outlook 2025

Furthermore, LR’s Management Board is adjusting the guidance for the 2025 financial year published on 25 April 2025. With regard to sales (revenue from goods sold), the Management Board now expects a stable development compared with the previous year. Previously, stable to moderately increasing sales had been forecast. EBITDA for the 2025 financial year is now expected to range between EUR 24.0 million and EUR 27.0 million – whereas the previous guidance anticipated significant EBITDA growth compared to the previous year’s figure of EUR 27.3 million. The revision of the EBITDA guidance is essentially due to increased or increasing costs in the areas of marketing and sales. This trend also continued in July, leading the Management Board to conclude that the previous guidance is unlikely to be achieved through catch-up effects or cost-saving measures.

The full report for the second quarter and the first half of 2025 will be available from 29 August 2025 on the corporate website: https://ir.lrworld.com/.

LR Group

Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.

Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence. 

The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe. 

In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.

LR currently has around 1,200 employees and hundreds of thousands of registered community members.

Contact:

PR contact: 
LR Health & Beauty SE    
Almut Kellermeyer     
Head of Corporate Communication     
Kruppstraße 55    
59227 Ahlen    
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/

IR contact: 
cometis AG
Thorben Burbach 
Unter den Eichen 7 | Gebäude D 
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
 

Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR Health & Beauty SE: Potential breach of Leverage Covenant as at 30 September 2025 – Management Board intends to enter into discussions with bondholders of the 2024/2028 bond regarding a precautionary resolution on a waiver of compliance with the Leverage Covenant as at 30 September 2025 and an amendment to the bond terms; adjustment of EBITDA guidance for the financial year 2025. 

Ahlen, 28 August 2025 – The Management Board of LR Health & Beauty SE (“LR” or the “Company”) resolved today to initiate precautionary negotiations with the holders of the 2024/2028 bond (ISIN: NO0013149658) concerning a proposal to amend the bond terms. The background to this decision is a potential breach by the Company of the covenant under Clause 13.2 of the bond terms, pursuant to which the Company must ensure that net debt in relation to EBITDA does not exceed the threshold of 4.50:1 as at 30 September 2025 (“Leverage Covenant”). Clause 13.2.1 (iii) of the bond terms provides that the Leverage Covenant decreases from 4.75:1 to 4.50:1 with effect from 1 July 2025. Based on the valuation and calculation information currently available, though still preliminary in nature, the Management Board assumes that compliance with the Leverage Covenant on the review date of 30 September 2025 is unlikely. This is due to EBITDA developing less favourably than expected, primarily attributable to increased or increasing costs in the areas of marketing and sales.

The Management Board has therefore resolved to enter into precautionary negotiations with the bondholders regarding an amendment to the bond terms – in particular the Leverage Covenant – and, if necessary, to request their consent to a waiver of the Leverage Covenant as at 30 September 2025. Furthermore, the Management Board will in due course provide information on the further course of action concerning the nature and timing of any vote on an amendment to the bond terms.

Furthermore, the Management Board of the Company is adjusting the guidance for the  financial year 2025 published on 25 April 2025. With regard to sales (revenue from goods sold), the Management Board now expects a stable development compared with the previous year. Previously, stable to moderately increasing sales had been forecast. EBITDA for the 2025 financial year is now expected to range between EUR 24.0 million and EUR 27.0 million – whereas the previous guidance anticipated significant EBITDA growth compared with the prior-year figure of EUR 27.3 million. The revision of the guidance is essentially due to increased or increasing costs in the areas of marketing and sales. This trend also continued in July, leading the Management Board to conclude that the previous guidance is unlikely to be achieved through catch-up effects or cost-saving measures.

IR Contact: 
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
phone: +49(0)611 - 205855-23
fax: +49(0)611 - 205855-66
email: burbach@cometis.de

End of inside information

LR Health & Beauty welcomes Jörg Körfer as new CEO – focus remains on growth and operational excellence

Ahlen, 21 July 2025 – LR Health & Beauty SE announces that Mr Jörg Körfer has been appointed Chief Executive Officer (CEO). He will take over the responsibilities of the previous members of the Management Board, Dr Andreas Laabs and Andreas Grootz, with effect from 1 August 2025. Both gentlemen will leave the company by mutual agreement on 31 July 2025. In order to further strengthen the management team in the future, the Supervisory Board is exploring options for another complementary member of the Management Board. 

Jörg Körfer has extensive expertise in global direct sales from his many years of management experience with international companies. Among other things, he spent 14 years at Vorwerk (CEO Kobold and CEO Thermomix) and served as Chairman of the Advisory Board at Bofrost for six years, as well as acting as CEO in an advisory capacity. He will now bring this experience to LR and continue to exploit the full potential of Europe’s leading social commerce platform in line with the strategy that has been pursued.

The Supervisory Board would like to express its sincere thanks to the two departing members of the Management Board for their trust and dedication. Under Dr Laabs’ leadership in particular, LR has developed excellently over the past eleven years and is ideally positioned to enter its next phase of growth. Since joining LR in 2014, Dr Laabs has played a key role in shaping the company and successfully transformed LR from a traditional direct sales model into a globally active social commerce company. The key milestones of his tenure include the digitalisation of the business model, several of LR’s most successful product launches, and infrastructure projects such as the insourcing of Aloe Vera Drinking Gels in 2018 and the opening of the IT hub in Athens, all of which have contributed significantly to LR’s current position.

Andreas Grootz is leaving the company after fourteen years. He established capital market-compatible governance structures at LR and drove forward the opening of new markets. 

The Supervisory Board is confident that Mr Körfer is the right successor to LR to continue the success story started by Dr Laabs and his team.


Contact:

Public Relations:
LR Global Holding
Almut Kellermeyer     
Head of PR / Public Affairs    
Kruppstraße 55    
59227 Ahlen    
Tel.: +49(0)2382 7813-106
Email: a.kellermeyer@LRworld.com
https://ir.lrworld.com/


Investor Relations:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Tel.: +49(0)611 – 205855-23
Fax: +49(0)611 – 205855-66
Email: burbach@cometis.de